Disruption of differentiation in human cancer: AML shows the way
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes. Recent studies of acute myeloid leukaemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer. This model involves lineage-specific transcription factors, which are involved in normal haematopoietic differentiation. These factors are often targeted in AML--either by direct mutation or by interference from translocation proteins. Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60,61).”
From Potential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element (2005) · cites this paper as [60]
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864 · cited 1×
“What is the role of lineage-specific transcription factors on stem cells, and how does this relate to AML? Although most of the blast cells from patients with AML clearly show a lineage- and stage-specific differentiation block, several studies support the idea that it is a disease that also involves the stem-cell com…”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Purification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“This could be applied either in treating bone marrow ex vivo with differentiation agents, followed by bone-marrow transplantation for re-introduction into the patient, or by local therapies, such as instillation into the lung by bronchoscop”
MethodOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Whereas AML1 falls into the category of transcription factors that are involved in the development of haematopoietic cells from haemangioblasts (SCL is another), and disruption of AML1 results in loss of all definitive haematopoiesi”
Background
Research works printed but not linked: 2
- Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
- Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML–RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
Cited by
Items 201–300 of 620
Nigten, J., Ridder, M. C. B.-D., Erpelinck-Verschueren, C. A. J., Nikoloski, G., van der Reijden, B. A., van Wageningen, S., van Hennik, P. B., de Witte, T., Löwenberg, B., & Jansen, J. H. (2005) · Leukemia · doi:10.1038/sj.leu.2403699 · Cited by 59
microRNAs as potential regulators of myeloid-derived suppressor cell expansion
El-Gazzar, M. M. (2013) · Innate Immunity · doi:10.1177/1753425913489850 · Cited by 47
“For a more in depth overview on the role of miRNAs in the development and regulation of the immune system I refer the reader to recent reviews.47,58,61 miRNAs involved in myeloid cell development and may affect MDSC expansion miR-29a miR-29a affects myelopoiesis,8 where its expression is normally down-regulated in com…”
BackgroundResultTargeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia
Hu, C.-L., Chen, B., Li, Z., Yang, T., Xu, C., Yang, R., Yu, P., Zhao, J., Liu, T., Liu, N., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00735-6 · Cited by 45
“As UHRF1 expression is positively correlated with cancer cell proliferation,37 it would be interesting to determine how UHRF1 would associate with the prognosis in a specific subtype of AML.”
BackgroundInfluentialN6-Methyladenosine Role in Acute Myeloid Leukaemia
Ianniello, Z., & Fatica, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082345 · Cited by 50
Zhuang, D., Qiu, Y., Kogan, S. C., & Dong, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510924200 · Cited by 48
Gatekeeper function of the RUNX1 transcription factor in acute leukemia
Niebuhr, B., Fischer, M., Täger, M., Cammenga, J., & Stocking, C. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.018 · Cited by 48
Bararia, D., Trivedi, A. K., Zada, A. A. P., Greif, P. A., Mulaw, M. A., Christopeit, M., Hiddemann, W., Bohlander, S. K., & Behre, G. (2008) · Leukemia · doi:10.1038/sj.leu.2405101 · Cited by 47
Ekberg, J., Holm, C., Jalili, S., Richter, J., Anagnostaki, L., Landberg, G., & Persson, J. L. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00473.x · Cited by 48
Testa, U., Riccioni, R., Biffoni, M., Diverio, D., Lo‐Coco, F., Foà, R., Peschle, C., & Frankel, A. E. (2005) · Blood · doi:10.1182/blood-2005-02-0540 · Cited by 44
Bastie, J.-N., Balitrand, N., Guidez, F., Guillemot, I., Larghero, J., Calabresse, C., Chomienne, C., & Delva, L. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0412 · Cited by 43
Marchwicka, A., Cebrat, M., Sampath, P., ewski, Å. Å. ⁄., & Marcinkowska, E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00125 · Cited by 48
“AML is characterized by the accumulation of transformed primitive hematopoietic blast cells, which lose their ability of normal differentiation and proliferation (4).”
BackgroundDisruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation
Wurm, A. A., Zjablovskaja, P., Kardosova, M., Gerloff, D., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Benoukraf, T., Fricke, S., Hilger, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00032-6 · Cited by 40
Self-citationTsiftsoglou, A. S., Bonovolias, I. D., & Tsiftsoglou, S. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.001 · Cited by 50
“Thismeans that disturbance of hematopoietic homeostasis in structure, intracellular level and function of transcription factors (activation and suppression) leaves no doubt that these molecules are critical factors in leukemic development (Tenen, 2003; Corey et al., 2007).”
BackgroundInfluentialTechnical Advance: Immunophenotypical characterization of human neutrophil differentiation
Mora-Jensen, H. I., Jendholm, J., Fossum, A., Porse, B. T., Borregaard, N., & Theilgaard‐Mönch, K. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311123 · Cited by 46
“The latter is consistent with the reported expression of RUNX1 in HPCs and its binding to promoters of several genes that are essential for early myeloid differentiation [14–16].”
BackgroundPatterning N‐type and S‐type neuroblastoma cells with Pluronic F108 and ECM proteins
Corey, J. M., Gertz, C. C., Sutton, T. J., Chen, Q., Mycek, K. B., Wang, B., Martin, A. A., Johnson, S. L., & Feldman, E. L. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32485 · Cited by 50
Ishikawa, Y., Nakayama, K., Morimoto, M., Mizutani, A., Nakayama, A., Toyoshima, K., Hayashi, A., Takagi, S., Dairiki, R., Miyashita, H., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.76 · Cited by 42
Hematopoietic stem cells and retroviral infection
Banerjee, P., Crawford, L. B., Samuelson, E., & Feuer, G. (2010) · Retrovirology · doi:10.1186/1742-4690-7-8 · Cited by 44
“Retroviral infection models such as FLV and M-MuLV, which induce leukemic states in mice, have emerged as powerful tools to study the molecular mechanisms associated with leukemogenesis and the generation of LSC/CSCs [74-78].”
BackgroundInfluentialApplication of vitamin D and vitamin D analogs in acute myelogenous leukemia
Cao, H. L., Xu, Y., de Necochea-Campion, R., Baylink, D. J., Payne, K. J., Tang, X., Ratanatharathorn, C., Ji, Y., Mirshahidi, S., & Chen, C.-S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.01.007 · Cited by 41
Olesen, L. H., Aggerholm, A., Andersen, B. L., Nyvold, C. G., Guldberg, P., Nørgaard, J. M., & Hokland, P. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05791.x · Cited by 50
“…significance of translocations, tandem duplications, methylation, and selective gene expression profiling Several findings suggest that acute myeloid leukaemia (AML) should be considered as a prototype disease for elucidating the role of molecular changes in cancer (Löwenberg, 2001; Tenen, 2003).”
BackgroundWang, Y., Jin, W., Jia, X., Luo, R., Tan, Y., Zhu, X., Yang, X., Wang, X., & Wang, K. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.388 · Cited by 45
“generally orchestrated by tightly tuned activities of hematopoietic transcription factors.(6) Accordingly, during the”
BackgroundDynamic transcriptomes of human myeloid leukemia cells
Wang, H., Hu, H., Zhang, Q., Yang, Y., Li, Y., Hu, Y., Ruan, X., Yang, Y., Zhang, Z., Shu, C., et al. (2013) · Genomics · doi:10.1016/j.ygeno.2013.06.004 · Cited by 44
Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
Pullarkat, S. T., Pullarkat, V. A., Kroft, S. H., Wilson, C. S., Ahsanuddin, A. N., Mann, K. P., Thein, M. M., Grody, W. W., & Brynes, R. K. (2009) · Journal of Hematopathology · doi:10.1007/s12308-009-0023-2 · Cited by 40
“This in turn causes a block in hematopoietic stem cell differentiation which in conjunction with additional genetic events leads to leukemic transformation [2, 3].”
BackgroundThe anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1
Jenal, M., Batliner, J., Reddy, V. A., Haferlach, T., Tobler, A., Fey, M. F., Torbett, B. E., & Tschan, M. P. (2010) · Leukemia · doi:10.1038/leu.2010.26 · Cited by 44
Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia
Li, X., Zhou, J., Wen, X., Zhang, T., Wu, D., Deng, Z., Zhang, Z., Lian, X., He, P.-F., Yao, X., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194549 · Cited by 40
“Acute myeloid leukemia (AML), a molecularly and clinically heterogeneous disease, is characterized by differentiation arrest and uncontrolled proliferation of myeloid progenitor cells, which ultimately interferes with the production of normal blood cells.(1) Although recent treatment advances in hematopoietic stem cel…”
BackgroundMcHale, C. M., & Smith, M. T. (2004) · American Journal of Hematology · doi:10.1002/ajh.20030 · Cited by 42
“AML1, are commonly mutated in AML cases without translocation [26].”
BackgroundThe inherent metastasis of leukaemia and its exploitation by sonodynamic therapy.
Trendowski, M. R. (2015) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2014.12.013 · Cited by 36
Bies, J., Šramko, M., Fares, J., Rosu‐Myles, M., Zhang, S., Koller, R. P., & Wolff, L. (2010) · Blood · doi:10.1182/blood-2009-08-238360 · Cited by 39
Mangiavacchi, A., Sorci, M., Masciarelli, S., Larivera, S., Legnini, I., Iosue, I., Bozzoni, I., Fazi, F., & Fatica, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11165 · Cited by 39
“com/oncotarget Acute myeloid leukemia (AML) is characterized by genetic and epigenetic alterations in progenitor cells that produce complete or partial blockage at different stages of myeloid differentiation and uncontrolled proliferation [3].”
BackgroundCancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii
Lun, Z., Lai, D., Wen, Y., Zheng, L., Shen, J.-L., Yang, T.-B., Zhou, W., Qu, L., Hide, G., & Ayala, F. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502599112 · Cited by 39
“The loss of differentiation is considered one of the most important events in the pathogenesis of many types of cancers, including leukemia (15).”
MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB–dependent promoters
Chan, E. M., Chan, R. J., Comer, E. M., Goulet, R. J., Crean, C., Brown, Z. D., Fruehwald, A. M., Yang, Z., Boswell, H. S., Nakshatri, H., et al. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.07.015 · Cited by 43
Aetiology of childhood leukemia
Lightfoot, T. J. (2005) · Bioelectromagnetics · doi:10.1002/bem.20140 · Cited by 44
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
Schardt, J., Eyholzer, M., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00870.x · Cited by 41
Gene-Expression Profiling in Acute Myeloid Leukemia
Grimwade, D. J., & Haferlach, T. (2004) · New England Journal of Medicine · doi:10.1056/nejme048040 · Cited by 39
Pal, P., Kanaujiya, J. K., Lochab, S., Tripathi, S. B., Bhatt, M. L. B., Singh, P. K., Sanyal, S., & Trivedi, A. K. (2011) · PROTEOMICS · doi:10.1002/pmic.201000720 · Cited by 38
“The increased understanding of apoptosis pathways has directed attention to the components of these pathways as potential targets for therapeutic agents [8].”
BackgroundKatzerke, C., Madan, V., Gerloff, D., Bräuer-Hartmann, D., Hartmann, J.-U., Wurm, A. A., Müller-Tidow, C., Schnittger, S., Tenen, D. G., Niederwieser, D., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472183 · Cited by 38
Self-citationYun, H., Narayan, N., Vohra, S., Giotopoulos, G., Mupo, A., Madrigal, P., Sasca, D., Lara‐Astiaso, D., Horton, S. J., Singh, S. A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00925-9 · Cited by 40
“However, although aberrant transcription is a cardinal feature of AML 13 , not all cases carry mutations in the above classes of proteins, suggesting that the effects of other common mutations, such as signaling alterations, indirectly converge on the same epigenetic, transcriptional and genome…”
Leeanansaksiri, W., Wang, H., Gooya, J. M., Renn, K., Abshari, M., Tsai, S., & Keller, J. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7014 · Cited by 37
Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia
Ayala, R. M., Martínez‐López, J., Albízua, E., Díez, A., & Gilsanz, F. (2008) · American Journal of Hematology · doi:10.1002/ajh.21332 · Cited by 43
Cho, J., Kim, J. J., Park, S. G., Lee, D. H., Lee, S. C., Kim, H., Park, B. C., & Cho, S. (2004) · PROTEOMICS · doi:10.1002/pmic.200400968 · Cited by 42
Chemical reprogramming of Caenorhabditis elegans germ cell fate
Morgan, C. T., Lee, M., & Kimble, J. E. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.282 · Cited by 37
Liu, J., Huang, Z., Chen, H., Qin, S., Chen, Y., Jiang, J., Zhang, Z., Luo, M., Ye, Q., Xie, N., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01713-9 · Cited by 40
“Nevertheless, the role of TFs in regulating tumor differentiation grades remains relatively unclear [11].”
BackgroundHaines, E., Nishida, Y., Carr, M. I., Montoya, R. H., Ostermann, L. B., Zhang, W., Zenke, F. T., Blaukat, A., Andreeff, M., & Vassilev, L. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-90500-3 · Cited by 39
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36
“1 strongly promotes myeloid differentiation, it has been thought to be a leukemia-suppressive gene.(42) Reducing PU.”
BackgroundSelf-citationTargeting fusion protein/corepressor contact restores differentiation response in leukemia cells
Racanicchi, S., Maccherani, C., Liberatore, C., Billi, M., Gelmetti, V., Panigada, M., Rizzo, G., Nervi, C., & Grignani, F. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600593 · Cited by 36
An evolutionarily conserved PTEN-C/EBPα-CTNNA1 axis controls myeloid development and transformation
Fu, C., Zhu, K.-Y., Mi, J., Liu, Y., Murray, S. T., Fu, Y., Ren, C., Dong, Z., Liu, Y., Dong, M., et al. (2010) · Blood · doi:10.1182/blood-2009-11-255778 · Cited by 38
Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia
Reckzeh, K., & Cammenga, J. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0573-1 · Cited by 43
“Upon malignant transformation, normal hematopoiesis is displaced by immature myeloid precursors, subsequently leading to a lack of mature blood cells resulting in anemia, neutropenia and thrombocytopenia [2, 3 ].”
BackgroundDownregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia
Yan, J., Wu, G., Chen, J., Xiong, L., Chen, G., & Li, P. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170936 · Cited by 36
“Acute myeloid leukemia (AML), the most common hematological fatal disease in adults, is characterized by differentiation arrest, increased self-renewal and malignant proliferation of clonal myeloid pre-cursors [1,2].”
Pal, P., Lochab, S., Kanaujiya, J. K., Kapoor, I., Sanyal, S., Behre, G., & Trivedi, A. K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.120 · Cited by 38
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPα
Ferrari‐Amorotti, G., Keeshan, K., Zattoni, M., Guerzoni, C., Iotti, G., Cattelani, S., Donato, N. J., & Calabretta, B. (2006) · Blood · doi:10.1182/blood-2006-01-011833 · Cited by 38
“Alteration of C/EBPα function is a common feature of leukemic cells (44); C/EBPα”
BackgroundLu, J., Wang, A.-N., Liao, H.-A., Chen, C., Hou, H., Hu, C., Tien, H., Ou, D., & Lin, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.004 · Cited by 36
Soliera, A. R., Mariani, S. A., Audia, A., Lidonnici, M. R., Addya, S., Ferrari‐Amorotti, G., Cattelani, S., Manzotti, G., Fragliasso, V., Peterson, L. F., et al. (2012) · Leukemia · doi:10.1038/leu.2012.19 · Cited by 36
cpsf1 is required for definitive HSC survival in zebrafish
Bolli, N., Payne, E. M., Rhodes, J., Gjini, E., Johnston, A. B., Guo, F., Lee, J.-S., Stewart, R. A., Kanki, J. P., Chen, A. T., et al. (2011) · Blood · doi:10.1182/blood-2010-08-304030 · Cited by 39
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML
Trinh, B. Q., Ummarino, S., Zhang, Y., Ebralidze, A. K., Bassal, M. A., Nguyen, T. M., Heller, G., Coffey, R., Tenen, D. E., van der Kouwe, E., et al. (2021) · Blood · doi:10.1182/blood.2020007920 · Cited by 38
Self-citationA Differentiation-Based Phylogeny of Cancer Subtypes
Riester, M., Attolini, C. S., Downey, R. J., Singer, S., & Michor, F. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000777 · Cited by 40
“Acute myeloid leukemia (AML) is a clonal disease characterized by the accumulation of myeloid progenitor cells in blood and bone marrow [18].”
BackgroundMethodCEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
Federzoni, E. A., Humbert, M., Torbett, B. E., Behre, G., Fey, M. F., & Tschan, M. P. (2014) · Scientific Reports · doi:10.1038/srep04261 · Cited by 38
Silberstein, L., Sánchez, M. J., Socolovsky, M., Liu, Y., Hoffman, G. J., Kinston, S., Piltz, S., Bowen, M., Gambardella, L., Green, A. R., et al. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0090 · Cited by 40
TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice
Xie, X., Zhang, W., Xiao, M., Wei, T., Qiu, Y., Qiu, J., Wang, H., Qiu, Z., Zhang, S., Pan, Y., et al. (2023) · Blood · doi:10.1182/blood.2022018619 · Cited by 41
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
Ueda, K., Kumari, R., Schwenger, E., Wheat, J. C., Bohorquez, O., Narayanagari, S.-R., Taylor, S. J., Carvajal, L. A., Pradhan, K., Bartholdy, B., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.006 · Cited by 36
“…classified as a so-called ‘class II’ (i.e. differentiation blocking) aberration which is caused by various genetic, epigenetic, and posttranslational mechanisms and is encountered in 60–70% of all AML patients (Gilliland and Tallman, 2002; Sive et al., 2016; Tenen, 2003; Will et al., 2015).”
BackgroundMulti-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation
Moreau-Gachelin, F. (2008) · Retrovirology · doi:10.1186/1742-4690-5-99 · Cited by 42
“Overviews on the genetic alterations found in AML are detailed in recent reviews [122-127].”
BackgroundRoos, J., Grösch, S., Werz, O., Schröder, P., Ziegler, S., Fulda, S., Paulus, P., Urbschat, A., Kuhn, B. R., Maucher, I. V., et al. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.001 · Cited by 37
LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia
Chong, P. S. Y., Zhou, J., Cheong, L.-L., Liu, S.-C., Qian, J., Guo, T., Sze, S. K., Zeng, Q., & Chng, W. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2321 · Cited by 33
“One important hallmark of AML is the acquisition of selfrenewal capacity in the leukemic blast cells (27) through the disruption of self-renewal pathways such as Hox and Wnt/b-catenin.”
BackgroundYamamoto, R., Kawahara, M., Ito, S., Satoh, J., Tatsumi, G., Hishizawa, M., Suzuki, T., & Andoh, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24774 · Cited by 33
“Transcription factors (TFs) play essential roles in the regulation of normal hematopoiesis [1].”
BackgroundDown-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias
Cilloni, D., Carturan, S., Gottardi, E. M., Messa, F., Messa, E., Fava, M., Diverio, D., Guerrasio, A., Lo‐Coco, F., & Saglio, G. N. (2003) · Blood · doi:10.1182/blood-2003-07-2256 · Cited by 33
Davis, A. G., Johnson, D. T., Zheng, D., Wang, R., Jayne, N. D., Liu, M., Shin, J., Wang, L., Stoner, S. A., Zhou, J., et al. (2021) · Blood · doi:10.1182/blood.2020005693 · Cited by 34
Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells
Peng, M., Huang, Y., Zhang, L., Zhao, X., & Hou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899502 · Cited by 39
Nanri, T., Uike, N., Kawakita, T., Iwanaga, E., Mitsuya, H., & Asou, N. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20734 · Cited by 37
S100A14: Novel Modulator of Terminal Differentiation in Esophageal Cancer
Chen, H., Ma, J., Sunkel, B. D., Luo, A., Ding, F., Li, L., He, H., Zhang, S., Xu, C., Jin, Q., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0317 · Cited by 35
“squamous cell–specific genes, and disruption of differentiation is an important characteristic of malignant tumors (30, 31).”
BackgroundMolecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model
Reckzeh, K., Bereshchenko, O., Mead, A. J., Rehn, M., Kharazi, S., Jacobsen, S. E. W., Nerlov, C., & Cammenga, J. (2012) · Leukemia · doi:10.1038/leu.2012.37 · Cited by 37
Genetic Interaction between Rb and K-ras in the Control of Differentiation and Tumor Suppression
Takahashi, C., Contreras, B., Bronson, R. T., Loda, M. F., & Ewen, M. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10406-10415.2004 · Cited by 33
“However, there is little understanding of the genetic pathways that contribute to tumorigenesis by disrupting the processes of differentiation (39).”
BackgroundCDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
Bertoli, S., Boutzen, H., David, L., Larrue, C., Vergez, F., Fernandez-Vidal, A., Yuan, L., Tamburini, J., Demur, C., Delabesse, É., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5706 · Cited by 31
“From a more general point of view, the ability of cells to escape terminal differentiation is one of the characteristics of cancer [40], and AML represents a paradigm for this phenomenon [41].”
BackgroundIdentification of TAZ as a Binding Partner of the Polyomavirus T Antigens
Tian, Y., Li, D., Dahl, J., You, J., & Benjamin, T. L. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12657-12664.2004 · Cited by 32
“RUNX1/AML1 and other members of the RUNX family are frequently altered in human cancers (15, 20, 22, 33).”
BackgroundDemajo, S., Uribesalgo, I., Gutiérrez, A., Ballaré, C., Capdevila, S., Roth, M., Zuber, J. A., Martín‐Caballero, J., & Croce, L. D. (2013) · Oncogene · doi:10.1038/onc.2013.501 · Cited by 32
Barbetti, V., Gozzini, A., Cheloni, G., Marzi, I., Fabiani, E., Santini, V., Sbarba, P. D., & Rovida, E. (2013) · Epigenetics · doi:10.4161/epi.23538 · Cited by 32
Naeini, M. M., & Ardekani, A. M. (2009) · PubMed Central · Cited by 40
Lidonnici, M. R., Audia, A., Soliera, A. R., di Prisco, M., Ferrari‐Amorotti, G., Waldron, T. J., Donato, N. J., Zhang, Y., Martinez, R. V. P., Holyoake, T. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1667 · Cited by 36
“The fact that C/EBPα is structurally or functionally inactive in the majority of cases of acute myeloid leukemia (3,4) further attests its essential role at the nodal points at which a balance in hematopoietic cell proliferation and differentiation needs to be maintained to prevent a potentially damaging disruption of…”
BackgroundZinovyeva, M. V., MONASTYRSKAYA, G. S., Kopantzev, E. P., Vinogradova, T. V., Костина, М. Б., Sass, A. V., Filyukova, O. B., Uspenskaya, N. Y., Sukhikh, G. T., & Sverdlov, E. D. (2009) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2009.01008.x · Cited by 31
García-Bates, T. M., Lehmann, G. M., Simpson‐Haidaris, P. J., Bernstein, S. H., Sime, P. J., & Phipps, R. P. (2008) · PPAR Research · doi:10.1155/2008/834612 · Cited by 34
“The resulting fusion protein arrests the maturation of myeloid cells at the promyelocytic stage and leads to the increased proliferation of promyelocytes [143].”
BackgroundAntiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells
Mortazavi, D., & Sharifi, M. (2018) · Cytotechnology · doi:10.1007/s10616-018-0241-5 · Cited by 32
“So, novel therapeutic strategies with less intensity but a higher rate of cure are needed urgently (Hasserjian et al. 2001; Mohammadiasl et al. 2016; Tenen 2003).”
BackgroundLSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia
Tatsumi, G., Kawahara, M., Yamamoto, R., Hishizawa, M., Kito, K., Suzuki, T., Takaori‐Kondo, A., & Andoh, A. (2019) · Leukemia · doi:10.1038/s41375-019-0614-6 · Cited by 30
Role of autophagy in acute myeloid leukemia therapy
Zhang, S., Niu, Y., Yuan, N., Zhang, A., Dan, C., Xu, Q.-P., Wang, L., Zhang, X., Zhao, W., Zhao, Y. S., et al. (2012) · 癌症:英文版 · doi:10.5732/cjc.012.10073 · Cited by 30
NAD Modulates DNA Methylation and Cell Differentiation
Ummarino, S., Hausman, C., Gaggi, G., Rinaldi, L., Bassal, M. A., Zhang, Y., Seelam, A. J., Kobayashi, I. S., Borchiellini, M., Ebralidze, A. K., et al. (2021) · Cells · doi:10.3390/cells10112986 · Cited by 31
MYND-less splice variants ofAML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21)
Kozu, T., Fukuyama, T., Yamami, T., Akagi, K., & Kaneko, Y. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20165 · Cited by 36
CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia
Korthuis, P. M., Berger, G., Bakker, B., Geugien, M., Jaques, J., de Haan, G., Schuringa, J. J., Vellenga, E., & Schepers, H. (2014) · Leukemia · doi:10.1038/leu.2014.259 · Cited by 34
Ekberg, J., Landberg, G., Holm, C., Richter, J., Wolgemuth, D. J., & Persson, J. L. (2004) · Oncogene · doi:10.1038/sj.onc.1208090 · Cited by 29
Ralhan, R., Chakravarti, N., Kaur, J., Sharma, C., Kumar, A., Mathur, M., Bahadur, S., Shukla, N. K., & Deo, S. V. S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21483 · Cited by 29
“Recent reports have suggested that defects in cell differentiation may have a vital role in cancer development.(77)”
BackgroundControl of Differentiation in Progression of Epithelial Tumors
Abelev, G. I., & Lazarevich, N. L. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95003-9 · Cited by 34
A Novel Application of Furazolidone: Anti-Leukemic Activity in Acute Myeloid Leukemia
Jiang, X., Sun, L., Qiu, J. J., Sun, X., Li, S., Wang, X., So, C. W. E., & Dong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072335 · Cited by 28
“The disruption of terminal differentiation is a salient feature in the pathogenesis of AML, and differentiation-based anticancer treatments, such as all-trans retinoic acid (ATRA), have been developed to overcome this block, thereby leading to clinical remission of APL patients [4,19].”
BackgroundSki Negatively Regulates Erythroid Differentiation through Its Interaction with GATA1
Ueki, N., Zhang, L., & Hayman, M. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10118-10125.2004 · Cited by 33
“In the case of normal hematopoiesis, this deregulation can contribute to the development of leukemia (22, 23, 26, 44).”
BackgroundOh, W. J., Rishi, V., Orosz, A., Gerdes, M. J., & Vinson, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2746 · Cited by 30
“Inactivation of C/EBPa prevents differentiation and it is mutated in many patients with acute myeloid leukemia (22).”
BackgroundReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia
Wang, Y., Zhang, T., Yang, D., Yao, D., Yang, L., Zhou, J., Deng, Z., Ma, J., Guo, H. Y., Wen, X., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv204 · Cited by 29
“Acute myeloid leukemia (AML), a common type of hematopoietic malignant disease, is characterized by increased self-renewal, differentiation arrest and malignant proliferation of leukemia progenitor cells, which ultimately interferes with normal production of blood cells (1).”
BackgroundMultiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia
Leinoe, E. B., Hoffmann, M. H., Kjærsgaard, E., & Johnsen, H. E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05156.x · Cited by 27
“…platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia Acute myeloid leukaemia (AML) is a clonal disease with a highly heterogeneous biology (Tenen, 2003), originating in primitive hematopoietic cells (Haase et al, 1995; Bonnet & Dick, 1997; Grimwade & Enver, 2004).”
BackgroundHirouchi, T., Takabatake, T., Yoshida, K., Nitta, Y., Nakamura, M. M., Tanaka, S., Ichinohe, K., Oghiso, Y., & Tanaka, K. J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.01.015 · Cited by 30
The Transcription Factor FOXA2 Suppresses Gastric Tumorigenesis In Vitro and In Vivo
Zhu, C.-P., Wang, J., Shi, B., Hu, P., Ning, B., Zhang, Q., Chen, F., Chen, W., Zhang, X., & Xie, W. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3290-4 · Cited by 27
HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells
Frank, C. L., Manandhar, D., Gordân, R., & Crawford, G. E. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0065-5 · Cited by 30
“1 transcription is known to be tightly regulated during normal hematopoietic differentiation with different expression levels facilitating key transition points in cell lineage [21, 22].”
BackgroundLee, L. Y. W., Woolley, C. E., Starkey, T., Biswas, S., Mirshahi, T., Bardella, C., Segditsas, S., Irshad, S., & Tomlinson, I. P. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1033 · Cited by 27
“There are two main theories to account for how an undifferentiated tumor might arise: (i) cancer cells are selected for their ability to downregulate differentiation gene(s), the so-called "dedifferentiation" hypothesis; or (ii) differentiation reflects the cell of origin of the cancer in the crypt (3, 4).”
BackgroundLi, X., Vradii, D., Gutiérrez, S., Lian, J. B., van Wijnen, A. J., Stein, J. L., Stein, G. S., & Javed, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20548 · Cited by 30
Chang, L. W., Payton, J. E., Yuan, W., Ley, T. J., Nagarajan, R., & Stormo, G. D. (2008) · Genome biology · doi:10.1186/gb-2008-9-2-r38 · Cited by 28
Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors in??the Treatment of Cancer
Buschbeck, M. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00002 · Cited by 29
Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt, L., Heyes, E., & Grebien, F. (2020) · BioEssays · doi:10.1002/bies.201900178 · Cited by 26
Zuo, Z., Cui, H., Li, M., Peng, X., Zhu, L., Zhang, M., Ma, J., Xu, Z., Meng, G., Deng, J., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510626 · Cited by 28
Metadata
- Authors
- Tenen, D. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tenen, Daniel G.
- ORCID
- Tenen, Daniel G.
- Venue
- Nature Reviews Cancer
- Published
- 2003-02
- Volume
- 3
- Issue
- 2
- Pages
- 89-101
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2050249118
- Cited by
- 612
- References
- 128
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 6 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 22 · 2016: 20 · 2015: 18 · 2014: 25 · 2013: 33 · 2012: 27
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- acute myeloid leukemia, cell differentiation, transcription factors, lineage-specific transcription factors, hematopoietic differentiation, transcription factor mutations, solid tumors
- MeSH terms
- Cell Differentiation, Humans, Mutation, Neoplasms, Transcription Factors, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.